L KyneSummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Toxin A-negative, toxin B-positive Clostridium difficileDenise Drudy
Centre for Food Safety, School of Agriculture, Food Science and Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland
Int J Infect Dis 11:5-10. 2007..This perspective describes these important toxin variant strains and highlights the need to use Clostridium difficile diagnostic methods that can detect both TcdA and TcdB...- Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoeaL Kyne
Gerontology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Lancet 357:189-93. 2001..The aim of this study was to determine whether an acquired immune response to toxin A, during an episode of C. difficile diarrhoea, influences risk of recurrence... - Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficileLorraine Kyne
Division of Gerontology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
Clin Infect Dis 34:346-53. 2002..On the basis of the findings of this study, a conservative estimate of the cost of this disease in the United States exceeds $1.1 billion per year... - Clostridium difficileL Kyne
Harvard Medical School, Gerontology Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Gastroenterol Clin North Am 30:753-77, ix-x. 2001..Ultimately, active or passive immunization against C. difficile may be an effective means of controlling the growing problem of nosocomial C. difficile diarrhea and colitis... - Factors associated with prolonged symptoms and severe disease due to Clostridium difficileL Kyne
Beth Israel Deaconess Medical Center, Gerontology Division, Boston, MA 02115, USA
Age Ageing 28:107-13. 1999..This study attempts to determine the proportion of patients in each category of severity and evaluate the risk factors for a more prolonged and complicated course... - Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficileDenise Drudy
Centre for Food Safety, School of Agriculture, University College, Dublin, Ireland
Infect Control Hosp Epidemiol 28:932-40. 2007..Between August 2003 and January 2004, we experienced an increase in the incidence of C. difficile-associated disease. We describe the investigation into and management of the outbreak in this article... - Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrheaStavros Sougioultzis
Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
Gastroenterology 128:764-70. 2005..The results of this study support the feasibility of active vaccination against C difficile and its toxins in high-risk individuals but must be validated in larger, randomized, controlled trials... - Human antibody response to surface layer proteins in Clostridium difficile infectionDenise Drudy
Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
FEMS Immunol Med Microbiol 41:237-42. 2004..6-376.3). Further studies which examine the specific anti-SLP antibody responses to the colonising strain are warranted to determine if immune responses to C. difficile SLPs play a role in protection from CDAD... - Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrheaLorraine Kyne
Gerontology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Infect Control Hosp Epidemiol 23:653-9. 2002..In the future, these "high-risk" patients may benefit from prophylaxis studies of novel agents being developed to prevent C. difficile diarrhea... 
Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin ASamer Aboudola
Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Infect Immun 71:1608-10. 2003..These findings support the feasibility of using a vaccine to protect high-risk individuals against C. difficile-associated diarrhea and colitis...- High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficileDenise Drudy
Centre for Food Safety, School of Agriculture, Food Science and Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland
J Antimicrob Chemother 58:1264-7. 2006..To determine the mechanism of high-level resistance to fluoroquinolone antimicrobials in toxin-A-negative, toxin-B-positive (A- B+) Clostridium difficile isolates... - gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027Denise Drudy
Emerg Infect Dis 13:504-5. 2007 
Immunoreactive cell wall proteins of Clostridium difficile identified by human seraAnne Wright
1Centre for Molecular Microbiology and Infection, Division of Cell and Molecular Biology, Imperial College, London SW7 2AZ, UK
J Med Microbiol 57:750-6. 2008..The role of these proteins as potential vaccine candidates and their roles in pathogenesis deserve further study...
Research Grants
- AGING AND THE HUMAN ANTIBODY RESPONSE TO C. DIFFICILELorraine Kyne; Fiscal Year: 2004..abstract_text> ..